Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial

被引:194
|
作者
Grotta, JC
Welch, KMA
Fagan, SC
Lu, M
Frankel, MR
Brott, T
Levine, SR
Lyden, PD
机构
[1] Univ Texas, Sch Med, Dept Neurol, Stroke Program, Houston, TX 77030 USA
[2] Henry Ford Hlth Sci Ctr, Dept Biostat & Res Epidemiol, Detroit, MI USA
[3] Henry Ford Hlth Sci Ctr, Dept Pharm Serv, Detroit, MI USA
[4] Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA
[5] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA
[6] Univ Cincinnati, Sch Med, Dept Neurol, Cincinnati, OH USA
[7] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA
[8] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA
关键词
deterioration; reocclusion; stroke; thrombolysis;
D O I
10.1161/01.STR.32.3.661
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Little is known in regard to cerebral arterial reocclusion after successful thrombolysis. In the absence of arteriographic information, the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trial investigators prospectively identified clinical deterioration following improvement (DFI) as a possible surrogate marker of cerebral arterial reocclusion after rt-PA-induced recanalization. Also, we identified any significant clinical deterioration (CD) even if not preceded by improvement. This observational analysis was designed to determine the incidence of DFI and CD in each treatment group, to identify baseline or posttreatment variables predictive of DFI or CD, and to determine any relationship between DFI, CD, and clinical outcome. Methods-DFI was defined as any 2-point deterioration on the NIH Stroke Scale after an initial 2-point improvement after treatment. CD was defined as any 4-point worsening after treatment compared with baseline. All data were collected prospectively by investigators blinded to treatment allocation. A noncontrast brain CT was mandated when a 2-point deterioration occurred. All cases were validated by a central review committee. Results-DFI was identified in 81 of the 624 patients (13%); 44 were treated with rt-PA and 37 were treated with placebo (P=0.48). DFI occurred more often in patients with a higher baseline NIH Stroke Scale score. CD within the first 24 hours occurred in 98 patients (16% of all patients); 43 were given rt-PA and 55 were given placebo (P=0.19). Baseline variables associated with CD included a less frequent use of prestroke aspirin and a higher incidence of early CT changes of edema or mass effect or dense middle cerebral artery sign. Patients with CD had higher rates of increased serum glucose and fibrin degradation products, and they also had higher rates of symptomatic intracranial hemorrhage and death. Patients who experienced either DFT or CD were less likely to have a 3-month favorable outcome. Conclusions-We found no association between DFI, CD, and rt-PA treatment, and no clinical evidence to suggest reocclusion. Deterioration was strongly associated with stroke severity and poor outcome and was less frequent in patients whose stroke occurred while they were on aspirin.
引用
下载
收藏
页码:661 / 668
页数:8
相关论文
共 50 条
  • [1] Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial
    Grotta, JC
    Welch, K
    Fagan, SC
    Lu, M
    Frankel, MR
    Brott, T
    Levine, SR
    Lyden, PD
    STROKE, 2001, 32 (01) : 382 - 382
  • [2] Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial
    Bruno, A
    Levine, SR
    Frankel, MR
    Brott, TG
    Lin, Y
    Tilley, BC
    Lyden, PD
    Broderick, JP
    Kwiatkowski, TG
    Fineberg, SE
    NEUROLOGY, 2002, 59 (05) : 669 - 674
  • [3] Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial
    Bruno, A
    Levine, SR
    Frankel, MR
    Brott, TG
    Lin, Y
    Tilley, BC
    Lyden, PD
    Broderick, JP
    Kwiatkowski, TG
    Fineberg, SE
    NEUROLOGY, 2002, 58 (07) : A337 - A338
  • [4] Hypertension and its treatment in the NINDS rt-PA Stroke Trial
    Brott, T
    Lu, M
    Kothari, R
    Fagan, SC
    Frankel, M
    Grotta, JC
    Broderick, J
    Kwiatkowski, T
    Lewandowski, C
    Haley, EC
    Marler, JR
    Tilley, BC
    STROKE, 1998, 29 (08) : 1504 - 1509
  • [5] A user's guide to the NINDS rt-PA stroke trial database
    Dachs, Robert J.
    Burton, John H.
    Joslin, Jeremy
    PLOS MEDICINE, 2008, 5 (05) : 705 - 708
  • [7] Antiphospholipid antibodies and outcome of acute ischemic stroke in the NINDS rt-PA stroke trial
    Tanne, D
    Levine, SR
    Brey, RL
    Lin, H
    Tilley, BC
    STROKE, 2003, 34 (01) : 279 - 279
  • [8] Clinical deterioration following intravenous rt-PA treatment
    Saqqur, M
    Molina, CA
    Siddiqui, MM
    Ribo, M
    Uchino, K
    Calleja, S
    Garami, Z
    Akhtar, N
    Salam, A
    Shuaib, A
    Rizvi, N
    Khan, K
    Demchuk, AM
    Alexandrov, AV
    STROKE, 2006, 37 (02) : 704 - 704
  • [10] Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial
    Tanne, D
    Levine, SR
    Brey, RL
    Lin, H
    Tilley, BC
    NEUROLOGY, 2003, 61 (08) : 1158 - U18